• Kabir Nath

    M.A., MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir Nath

    M.A., MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the U.K., France, Spain, India, Singapore, China and the US. Kabir joined Otsuka to head the North American pharmaceutical business in March 2016, with direct responsibility for Otsuka America Pharmace?uticals, Inc., Avanir and Otsuka Canada. Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol Myers Squibb. Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio ñ including d?rugs for HIV, hepatitis B and hepatitis C and immunosuppression - in the USA. Previously he was Senior Vice President, Global Commercialization - Virology & Neuroscience, leading global strategy for these two disease areas. In addition he served as interim head of Emerging Markets for much of 2012. Kabir joined BMS in Singapore in 2003 as vice president for South East Asia/Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed president, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries. Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the U.K., Europe and Asia. Kabir holds an MA from Kingís College, University of Cambridge, and an MBA with Distinction from INSEAD.
  • Louis Allesandrine

    VP, Nephrology and MDD Sales & Marketing

    Louis Allesandrine

    VP, Nephrology and MDD Sales & Marketing

    "At Otsuka, we drive innovation and creativity by following the company philosophy; Taking the Road Less Traveled. It helps us address unmet needs of patients, their caregivers, and healthcare professionals, keeping us focused on doing our part to provide better health worldwide."

    As Vice President of Nephrology and MDD Sales & Marketing at Otsuka America Pharmaceutical, Inc. (OAPI), Louis is responsible for leading the strategic development and execution of our U.S.-based commercial nephrology and MDD businesses. This includes JYNARQUEÆ (tolvaptan), SAMSCAÆ (tolvaptan), and the co-promotion of SPRYCELÆ (dasatinib) with Bristol-Myers Squibb and our clinical stage collaborations with Astex Pharmaceuticals, a member of the Otsuka Group. Louis joined OAPI in 2017 after 25 years of commercial experience in the pharmaceutical industry. Prior to OAPI, he served six years as Vice President, Oncology Marketing, at Boehringer Ingelheim. Earlier in his career, he held a series of leadership positions in sales and marketing focused in the areas of oncology and urology specialty care. Louis received a Master of Business Administration from Quinnipiac University
  • Karen Gally

    J.D.
    VP & General Counsel, Legal Affairs

    Karen Gally

    J.D.
    VP & General Counsel, Legal Affairs

    As Vice President & General Counsel at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Karen focuses on the legal issues of clinical development, product commercialization, and corporate governance. Karen has the privilege to support pharmaceutical compounds from ìcradle to grave,î from early clinical development through loss of exclusivity and beyond. Karen's work primarily focuses on the Otsuka compounds used to treat serious mental illness including schizophrenia, major depression, bipolar I disorder, and Alzheimerís disease; I have also worked in the areas of oncology, neurology, and renal disease. Karen's work also involves supporting the Boards of Directors of OPDC and its sister company, Otsuka America Pharmaceutical, Inc. (OAPI); she is also Corporate Secretary to the Board of Directors of Neurovance, an Australian subsidiary of OAPI. Prior to joining Otsuka in 2003, Karen was an Associate with Epstein, Becker & Green in the Washington, D.C., office in the national health law practice group. From 1996 through 2003, she represented national healthcare companies in the areas of durable medical equipment, home healthcare, and pharmaceuticals in criminal and civil investigations. Before attending law school, Karen worked in public relations and public policy for a division of Beth Israel Medical Center in New York City, and for the New York State Conference of Blue Cross and Blue Shield Plans in Albany. Karen earned her J.D. from the University of Maryland Law School in Baltimore, and a Bachelor of Arts from Dartmouth College in Hanover, New Hampshire.
  • Christoph Koenen

    M.D., MBA
    SVP & Chief Medical Officer

    Christoph Koenen

    M.D., MBA
    SVP & Chief Medical Officer

    As Senior Vice President and Chief Me?dical Officer of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Christoph helps define the global R&D strategy and have direct responsibility for taking all compounds for global registration from first in human through to Regulatory Approval. As a seasoned clinical development leader, Christoph works collaboratively across the leadership team to help refine the clinical development strategy and roadmap for implementation. In addition, Christoph has oversight of clinical management to ensure studies are completed on time and within budget. In his area, Christoph continues to invest in new and innovative means of conducting clinical trials as well as other innovative ways of data collection. Christoph's responsibilities include medical affairs which consists of medical strategy and field medical. In medical affairs Christoph and team are the bridge between the research and the commercial part of the organization. Before joining Otsuka in 2019, Christoph was Head of Cardiovascular Medicine and Development at Bristol-Meyers Squibb (BMS). In this role Christoph helped BMS to develop its next generation of cardiovascular medicines. Christoph was also responsible for ongoing data generation for Eliquis (one of the most successful drugs in the industry) and was a catalyst behind the creation of the largest Real World Evidence data generation initiative created in the field of anticoagulation. Prior to joining BMS in 2011, Christoph worked for Novo Nordisk in various medical and development functions in Europe, as well as in the US. Christoph's dual medicine-business background has informed his ability to combine scientific innovation with a strategic approach to business-development opportunities, regulatory navigation, and global-patient access solutions. Christoph received his medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany, in 1994. He also holds an MBA from Schiller International University. Christoph is board certified in internal medicine and diabetology.
  • Nick Kurahashi

    M.S.
    VP, Global CNS Business

    Nick Kurahashi

    M.S.
    VP, Global CNS Business

    Nick is Vice President of the Global CNS Business for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). He is responsible for alliance management with companies that Otsuka has alliances with, as well as development of global clinical and commercialization strategy for central nervous system (CNS) and digital innovation products. His career at Otsuka began in 1988 as a researcher and organic chemist for psychiatry disorders in the CNS group in Japan and has steadily progressed to the clinical and commercial side, as well as taking on global roles. In 1996, he became the Product Development Coordinator responsible for the development and coordination of the global clinical and commercialization plan for the anti-platelet agent. Starting in 2000, he was the International Manager of ABILIFYÆ (aripiprazole) at Otsuka America Pharmaceutical, Inc (OAPI). He managed coordination between the U.S., E.U., Japan, and Asia, as well as Alliance Management. By 2003, he became the ABILIFY Product Marketing Manager, leading the brand in Japan, until beginning his current role in 2010. Nick had the unique opportunity and honor of contributing to the research and development and commercialization of ABILIFY. During his tenure at Otsuka, global mobility afforded him an opportunity to exchange knowledge with peers, bringing different perspectives and problem-solving abilities to the conversation based on professional backgrounds. Today, he is passionate about the future of Otsuka and how the company can leverage technology and digital innovation to advance healthcare and help make the world a healthier place for all. Prior to joining Otsuka, Nick received a Master of Science in pharmacy from Gifu Pharmaceutical University.
  • Angela Colon-Mahoney

    M.S.
    VP, Otsuka-People and Services

    Angela Colon-Mahoney

    M.S.
    VP, Otsuka-People and Services

    As VP of Otsuka-People and Services, Angela leads the Human Resources function, Language Services, and the Information Resource Centers for Otsuka in the U.S. and serve as a member of Otsuka's Executive Leadership Team. Angela is helping Otsuka transition to one U.S. business on the Road to 2030 with a strategic focus on CEO and succession planning, organization design, and advanced human capital practices. Angela's focus is on building capabilities in people analytics and streamlined HR systems, business partner consultancy, talent and leadership development, change management, and organizational effectiveness. Angela also oversees Otsukaís Total Rewards program, HRIS, HR Enablement and Recruitment, and the North America ReadyNOW team of sales personnel focused on a unique sales profile to accelerate the core commercial business and enable a long-term multi-product strategy for CNS, Nephrology, and Digital Medicine. Before joining Otsuka in 2018, Angela served in a variety of senior roles leading human resources and transformations in global companies across multiple industries. Angela was the HR Leader at The Estée Lauder Companies, where she led global shared service and technology transformations while working with the CEO and c-suite officers around the globe. Prior to Estée Lauder, Angela was Global Talent and HR Leader for Tyco, where she led the enterprise's talent management strategy and global performance management processes and systems. Angela has also served as an Organization Development Consultant for Mercer Consulting. She has built global centers of expertise in talent acquisition, talent management, learning and development, total rewards, and HR communications. Angela has a Bachelor of Arts in Psychology from St. John's University and a Master of Science in Organization Change Management from The New School University.
  • Tifani L. McCann

    Ph.D.
    VP and Chief Data Officer (CDO)

    Tifani L. McCann

    Ph.D.
    VP and Chief Data Officer (CDO)

    As Vice President and Chief Data Officer of Otsuka America Pharmaceutical, Inc. (OAPI), Tifani leads the team that is responsible for harnessing the organizationís existing data assets across all lines of business as well as procuring essential data from external sources, and converting these into actionable insights. She guides the organizationís data science strategy to ensure these insights provide meaningful business value, so that they can be integrated into portfolio decision making, clinical trial design, business analytics and market research for commercial operations. Tifani has more than 20 years of Pharma and CRO leadership experience which include building and transforming biometrics capabilities, organizations and clinical data systems. Before joining Otsuka in 2019, she served as Global Head of Biostatistics and Data Analytics at Covance. In this role, Tifani led the biostatistics and statistical programming organizations as well as the risk-based monitoring and medical data review organizations. Prior to her experience at Covance, Tifani was at Bristol-Myers Squibb serving in various roles of increasing responsibility including the Biometricsí therapeutic area head for Immunosciences to leading the business operations of the Global Biometrics Sciences organization as well as Global Head of the Data Strategy and Solutions organization
  • Jennifer McGee, Esq.

    J.D.
    Global Chief Compliance Officer

    Jennifer McGee, Esq.

    J.D.
    Global Chief Compliance Officer

    As Global Chief Compliance Officer, Jennifer is responsible for overseeing Otsukaís management of compliance programs through auditing, monitoring, investigations, remediation, training, compliance communications and reporting. Jennifer joined Otsuka in January 2011 as Senior Compliance Counsel and assumed the responsibilities of Chief Compliance Officer in May 2015. Prior to joining Otsuka, she worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers in government investigations and lawsuits. She also served in the U.S. Army for more than 13 years, trying more than 70 felony criminal trials. Jennifer retired from the U.S. Army Reserve in 2017. Jennifer earned her bachelorís degree from St. Lawrence University and her juris doctor degree from the University of Maryland School of Law.
  • Robert McQuade
    Robert McQuade

    Ph.D.
    EVP & Chief Strategic Officer

    Robert McQuade

    Robert McQuade

    Ph.D.
    EVP & Chief Strategic Officer

    Otsuka is not right for everyone. It is a dynamic environment for those who wish to be challenged and engaged every day. We are focused on bringing important new drugs and innovations to patients, especially for those with serious mental illness. This has been my personal goal throughout my career and through Otsuka I believe that I have in fact made a difference in the lives of these patients.

    As Executive Vice President and Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Robert is responsible for coordinating the development strategy for Otsukaís compounds across their life cycles. He has more than 30 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness. Robertís career started as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough and gradually advanced to Associate Director of CNS Pharmacology. In this role, he supervised the biochemical pharmacology group in their efforts to discover new drugs for mental illness, including schizophrenia and Alzheimerís disease. Robert next joined Global Medical Affairs at Bristol-Myers Squibb (BMS). While at BMS, he was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder. More importantly, he was part of the team that helped form the alliance between BMS and Otsuka for the development and commercialization of ABILIFYÆ (aripiprazole). It was only natural that Robert ultimately joined Otsuka in 2004 to oversee global medical affairs for ABILIFY. His roles have grown over the years, and now he is responsible for the global development strategy for Otsukaís compounds in the CNS, cardio-renal, and oncology therapeutic areas. In addition, he is involved in many of Otsukaís external collaborations and business development initiatives. Robert received a Bachelor of Science from Davidson College and a Ph.D. from the University of North Carolina, Chapel Hill.
  • Innes Meldrum

    VP, CNS Sales and Marketing

    Innes Meldrum

    VP, CNS Sales and Marketing

    "My motivation for working at Otsuka is that most companies talk about innovation but at Otsuka it's part of the DNA. One of my favorite quotes is that "the definition of insanity is doing the same thing and expecting different results" by Albert Einstein. I believe strongly that the essence of marketing is effectively differentiating vs the competition and to do this requires adopting new approaches that challenge conventional thinking and by implication the status quo. Otsuka provides an environment that actively encourages this."

    As Vice President of CNS Sales & Marketing at Otsuka America Pharmaceutical, Inc. (OAPI), Innes is responsible for leading the Marketing and Sales teams to create and execute innovative, differentiated marketing strategies and tactics. He also has responsibility for the commercialization of Otsukaís central nervous system and cardio-renal pipelines. He has more than 20 years of experience in executive strategic, marketing, sales, and business operations in both the pharmaceutical and technology industries. Innes joined Otsuka in 2017. Prior to Otsuka, he spent three years at Orexo as Head of U.S. Sales and Marketing, focused on the opioid addiction market. Before this, he worked in a variety of global and U.S. roles at Novartis and, most recently, was Head of Sales and Marketing of the U.S. NeuroPsychiatry business. Prior to that, he spent 10 years working in the technology industry with Nortel Networks, HP, and Agilent Technologies, focused on developing solutions for the wireless telecoms industry. Innes earned his Bachelor of Engineering in electrical and electronic engineering from the University of Strathclyde in Glasgow, Scotland.
  • Edward Stelmakh
    Edward Stelmakh

    CPA, CMA
    SVP, CFO

    Edward Stelmakh

    Edward Stelmakh

    CPA, CMA
    SVP, CFO

    "My primary motivation for working at Otsuka is to help define and execute on our corporate strategic goals as we deal with continuously changing landscape of internal and external challenges and opportunities. I have a real passion for driving positive change and working in an environment where one can make significant impact across a broad spectrum of areas. I truly believe that the only constant in life is change and Otsuka’s success as an organization is hinged upon its willingness and ability to embrace changes occurring in the pharmaceutical industry landscape."

    As Senior Vice President and CFO at Otsuka America Pharmaceutical, Inc. (OAPI), Ed is responsible for all areas of finance supporting the U.S. business, including Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). In his current role, Ed oversees accounting, business support, financial planning and analysis, treasury, M&A , internal controls, and tax functions. In addition to finance, he manages the established product portfolio, market access pricing support, and strategic outsourcing functions. Prior to joining Otsuka in 2015, Ed spent six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, he held a variety of positions with growing responsibilities within Organon (Schering-Plough), Mylan, Sanofi-Aventis, and Johnson & Johnson. His background includes a broad spectrum of financial, commercial, and operational leadership roles, including eight years of international assignments in the Netherlands and Russia. Ed received his bachelorís degree in finance from Towson University and his M.B.A. from the University of Baltimore. He is also a certified public accountant (New Jersey) and a certified management accountant.
  • Remy Sukhija

    SVP, Commercial Operations

    Remy Sukhija

    SVP, Commercial Operations

    Mr. Sukhijaís 25-year career encompasses leadership roles at Global, European and US organizations in the pharma/biotech industry. He joined the Otsuka family of companies at the beginning of 2017 as SVP, Commercial Operations. In his current role, Mr. Sukhija is responsible for Market Access, Government Affairs, Patients Services, Business Analytics & Planning, Sales Operations, and Sales Training functions at Otsuka America Pharmaceutical Inc. (OAPI) and Avanir. Prior to this role, Mr. Sukhija served as Chief Operating Officer at a small private biotech, Merganser Biotech, for two years where he was responsible for Commercial Strategy, Business Development, Finance, and all other Business Operations functions. Between 2010 and 2015, Mr. Sukhija served as Vice President and leader of the Hemophilia Business Unit at Biogen, which he built and led from its inception. His work at Biogen culminated in two very successful product launches in hematology in 2014. Prior to working at Biogen, Mr. Sukhija held a number of different commercial and operational leadership roles at Pfizer and GSK.
  • Andrew Wright
    Andrew Wright

    VP, Business Unit Head, Digital Medicine

    Andrew Wright

    Andrew Wright

    VP, Business Unit Head, Digital Medicine

    “Our journey with digital medicine was inspired by the late President of Otsuka, Dr. Taro Iwamoto. He drove the value of innovation. He challenged us to think differently about solving unmet healthcare needs through alliances and technology. We are working to fulfill this vision by going beyond the pill.”

    As Vice President, Business Unit Head, Digital Medicine, at Otsuka America Pharmaceutical, Inc. (OAPI), Andrew is responsible for leading the commercialization of wearable computing and digital products. The Digital Medicine teamís goal is to enable improved patient medication adherence and better-informed physician decision-making to tailor treatment to patientsí needs. He has more than 25 years of U.S. and global experience in commercial leadership roles in the pharmaceutical industry. Earlier, Andrew worked at Novartis as Head, HCP Digital/Multi-Channel Marketing, Global Commercialization, and was responsible for identifying and developing digital and multi-channel solutions that enhanced customer engagement. Prior to that, as Executive Director, Insights & Innovation, he led and developed a team responsible for customer/brand insights and innovation across the U.S. pharmaceutical business. Andrew also held senior marketing and sales roles for in-line and launch brands at Novartis, producing consistently strong results. At Pharmacia, he led the launch of a major product in 11 markets across Europe. Andrew has a Bachelor of Science in business administration from Crewe and Alsager College.

NEUROSCIENCE

Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.